William Blair analyst Andrew Brackmann has maintained their bullish stance on MDXH stock, giving a Buy rating yesterday.
Andrew Brackmann has given his Buy rating due to a combination of factors including MDxHealth’s positive fourth-quarter update, which aligned with financial expectations. The company reported a 21% year-over-year increase in revenue and maintained its guidance, indicating a strong growth trajectory. Additionally, MDxHealth is on course to achieve AEBITDA positivity by the first half of 2025, which is expected to boost investor confidence by demonstrating the company’s ability to self-fund and manage upcoming financial obligations.
Brackmann also notes that the current valuation of MDxHealth’s shares, at one times the 2025 revenue, does not fully reflect the company’s growth potential and commercial infrastructure. He anticipates that the valuation multiple could expand over the next year, further supporting the Buy rating. Overall, the combination of these financial metrics and strategic positioning underpins the positive outlook on MDxHealth’s stock.
In another report released yesterday, TD Cowen also reiterated a Buy rating on the stock with a $7.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com